Editas Medicine (EDIT) Stock Overview
A clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
EDIT Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Editas Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$4.54 |
| 52 Week Low | US$1.35 |
| Beta | 2.14 |
| 1 Month Change | -9.38% |
| 3 Month Change | 72.62% |
| 1 Year Change | 110.14% |
| 3 Year Change | -69.82% |
| 5 Year Change | -91.24% |
| Change since IPO | -84.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| EDIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | -0.5% | 0.5% |
| 1Y | 110.1% | 44.4% | 25.4% |
Return vs Industry: EDIT exceeded the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: EDIT exceeded the US Market which returned 25.5% over the past year.
Price Volatility
| EDIT volatility | |
|---|---|
| EDIT Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EDIT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EDIT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 87 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Editas Medicine, Inc. Fundamentals Summary
| EDIT fundamental statistics | |
|---|---|
| Market cap | US$286.87m |
| Earnings (TTM) | -US$108.95m |
| Revenue (TTM) | US$38.69m |
Is EDIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDIT income statement (TTM) | |
|---|---|
| Revenue | US$38.69m |
| Cost of Revenue | US$80.96m |
| Gross Profit | -US$42.27m |
| Other Expenses | US$66.69m |
| Earnings | -US$108.95m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | -109.24% |
| Net Profit Margin | -281.59% |
| Debt/Equity Ratio | 0% |
How did EDIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/13 06:30 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Editas Medicine, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Joel Beatty | Baird |
| Alec Stranahan | BofA Global Research |